key: cord-0877412-rp1rx1bn authors: Chase, J. Geoffrey; Chiew, Yeong-Shiong; Lambermont, Bernard; Morimont, Philippe; Shaw, Geoffrey M.; Desaive, Thomas title: In-Parallel Ventilator Sharing during an Acute Shortage: Too Much Risk for a Wider Uptake date: 2020-11-01 journal: Am J Respir Crit Care Med DOI: 10.1164/rccm.202006-2420le sha: 3f9ce0b99bfa885e30af53f575e66ad3e897a748 doc_id: 877412 cord_uid: rp1rx1bn nan To the Editor: We read with interest the article by Beitler and colleagues on ventilator sharing among patients with coronavirus disease (COVID-19)-associated acute respiratory distress syndrome (1) . The COVID-19 pandemic has forced clinicians to develop strategies to avoid denying care because of ventilator capacity shortages induced by patient demand surges. Nevertheless, the safety of these strategies has been difficult to guarantee, as summarized in a recent multisociety consensus statement (2). Beitler and colleagues implemented a careful protocol for a shared, in-parallel (i.e., simultaneous, breathing-together) ventilation circuit (1) . Their methodology demonstrated the feasibility of ventilator sharing but at the cost of several major limitations we believe could prevent generalization or wider uptake, including the following: 1. Patient compatibility criteria are crucial and require time and expertise. Unfortunately, COVID-19 "overrun," as we will call it, is a situation in which time is "negative." For many clinical staff, there is little time or ability to spend matching patients and monitoring it when patient course diverges. Many hospitals worldwide do not have the nursing levels of the United States. 2. The patient-specific monitoring required is necessary but adds circuit complexity, cost, and technology that may not be available in many centers worldwide. It will also require significantly more technical expertise than is available outside major center hospitals. 3. Rescue ventilators (as a safety measure if shared ventilation fails) may not be available or may understandably also be in use in such a situation. 4. Pressure control when patients breathe together does not ensure that lung damage from divergent patient courses does not occur. Driving pressure and barotrauma are an issue if compliance rises significantly for one patient and similarly for underventilation and a need for greater pressure in one patient. This approach thus puts great weight on not only patient matching but also matching and tracking patient course to avoid damage. It may work in a limited trial and study but not necessarily in a COVID-19 "overrun" situation, in which staffing capability is stretched to the limit. 5. The authors state, "Patient selection and management require considerable expertise to ensure safety. Therefore, we recommend a regional referral model wherein ventilator sharing is restricted to expert centers, and patients and ventilators move throughout the region accordingly." However, it requires significant time, cost, and effort to move infectious patients. It also implies greater risk for a select set of patients in the receiving center(s), which may not be ethical or provide equity of access to care for patients. Importantly, we admire this result but feel in-parallel ventilation carries too much risk and difficulty to implement safely. We would thus draw the authors' attention to the concept of in-series breathing (patients breathe one after the other) in a simply implemented active circuit (3) as a safer alternative. It allows individualized positive end-expiratory pressure and driving pressure to account for differences between patients and reduces risk of harm because patients breathe separately (not together). Thus, Beitler and colleagues (1) developed excellent results in a limited test situation but added significant complexity and cost per patient, which may not be feasible in general or in COVID-19 overrun. The use of in-parallel breathing requires significant matching of patient condition and monitoring of time course to assess risks of barotrauma or volutrauma (even with pressure control) as well as a risk of underventilation. All these risks are well-known to be difficult to monitor and assess in the best of times. A COVID-19 overrun situation demanding ventilator doubling is not the best of times. We suggest in-series breathing as a safer solution. n To the Editor: In a recent article, Beitler and colleagues described their methodology and lessons learned from ventilator sharing during the acute shortage caused by the coronavirus disease (COVID-19) pandemic (1). We applaud their efforts during unprecedented circumstances, as we similarly assessed the safety and feasibility of ventilator sharing at a time of near depletion. In their assessment, each patient was matched with identical ventilator settings before sharing pressure-control ventilation. In our assessment, we used the Vent Multiplexor device to modulate flow in a volume-control mode and permit individual adjustments of VT to two patients. At baseline, patient A had a VT of 350 ml (5.5 ml/kg predicted body weight), driving pressure of 14 cm H 2 O with positive endexpiratory pressure (PEEP) of 14 cm H 2 O, and pH 7.36 with Pa CO 2 56 mm Hg; patient B had a VT of 450 ml (6.8 ml/kg predicted body weight), driving pressure of 12 cm H 2 O with PEEP of 10 cm H 2 O, and pH 7.42 with Pa CO 2 54 mm Hg. Each had different static lung compliances (A = 25 ml/cm H 2 O; B = 37.5 ml/cm H 2 O). Both had a respiratory rate of 20 breaths/min and required vasopressor support and neuromuscular blockade for the assessment; neither had underlying lung disease. Before the assessment, consent was obtained from both patients' families. The Vent Multiplexor was assembled within the circuit described in Figure 1 . In the assessment, the device was adjusted to deliver different flow ratios to patients, with vitals, end-tidal carbon dioxide, plateau pressures, and arterial blood gases monitored over a 2-hour period. The immunology of asthma Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with highdosage inhaled corticosteroids and long-acting b 2 -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial ZONDA Trial Investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function Population pharmacokinetics and pharmacodynamics of benralizumab in healthy volunteers and patients with asthma Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response The use of benralizumab in the treatment of near-fatal asthma: a new approach Ventilator sharing during an acute shortage caused by the COVID-19 pandemic Consensus statement on multiple patients per ventilator Safe doubling of ventilator capacity: a last resort proposal for last resorts